Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBT Margin (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed EBT Margin for 8 consecutive years, with 245.06% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin rose 9203.0% year-over-year to 245.06%; the TTM value through Mar 2026 reached 698.37%, down 22544.0%, while the annual FY2025 figure was 892.02%, 33567.0% down from the prior year.
  • EBT Margin hit 245.06% in Q1 2026 for Kymera Therapeutics, up from 3414.15% in the prior quarter.
  • Across five years, EBT Margin topped out at 40.44% in Q4 2023 and bottomed at 3414.15% in Q4 2025.
  • Average EBT Margin over 5 years is 901.07%, with a median of 470.3% recorded in 2022.
  • On a YoY basis, EBT Margin climbed as much as 22575bps in 2025 and fell as far as -232118bps in 2025.
  • Kymera Therapeutics' EBT Margin stood at 239.72% in 2022, then soared by 83bps to 40.44% in 2023, then crashed by -2603bps to 1092.97% in 2024, then plummeted by -212bps to 3414.15% in 2025, then skyrocketed by 93bps to 245.06% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 245.06%, 3414.15%, and 3350.9% for Q1 2026, Q4 2025, and Q3 2025 respectively.